Many targeted cancer therapies suppress T cell immune responses

(The Wistar Institute) New research from The Wistar Institute demonstrated that dozens of these targeted therapies suppressed the activity of T cells that could actually help fight tumors. While studying the FDA-approved targeted therapy trametinib, the researchers also found that pairing it with a signaling protein 'superagonist' stimulated T cell activity while preserving the cancer-blocking effects of the cancer treatment.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Abstract Throughout various eras of breast cancer therapy, postmastectomy radiation therapy (PMRT) has played an important role in the treatment of locally advanced breast cancer. PMRT decreases locoregional recurrence and may improve overall survival in patients with tumors over 5 cm or positive lymph nodes. As novel cancer therapies improve survival in breast cancer, the role of radiation therapy is evolving. Individualized recommendations for PMRT dependent on pathologic response after neoadjuvant systemic therapy are under investigation. This review summarizes the role of PMRT during breast cancer therapy...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Surg Clin North Am Source Type: research
(MedPage Today) -- With immune checkpoint inhibition, rheumatic adverse events may become more common than RA
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news
Publication date: Available online 14 December 2017Source: Materials TodayAuthor(s): Emily Reiser Evans, Pallavi Bugga, Vishwaratn Asthana, Rebekah DrezekAbstractCancer immunotherapy, or the utilization of the body’s immune system to attack tumor cells, has gained prominence over the past few decades as a viable cancer treatment strategy. Recently approved immunotherapeutics have conferred remission upon patients with previously bleak outcomes and have expanded the number of tools available to treat cancer. Nanoparticles – including polymeric, liposomal, and metallic formulations – naturally traffic to th...
Source: Materials Today - Category: Materials Science Source Type: research
In this study, we identified pyruvate kinase M2 (PKM2) as a direct target of HCA by use of biochemical methods including affinity chromatography, drug affinity responsive target stability, and cellular thermal shift assay. PKM2 is up-regulated in multiple cancer types and is considered as a potential target for cancer therapy. HCA binds directly to PKM2 and selectively decreases the phosphorylation of PKM2 at Tyr105, indicating a potential anti-proliferative effect on prostate cancer cells.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Tags: Original Articles Source Type: research
Publication date: Available online 7 July 2018Source: Journal of Molecular LiquidsAuthor(s): Samira Malekmohammadi, Hassan Hadadzadeh, Zahra AmirghofranAbstractThe purpose of this study is to develop a targeted drug delivery system containing folic acid-conjugated dendritic amino mesoporous silica nanoparticles (DFMSNs) loaded with a cyclometallated gold(III) complex, [Au(bzpy)Cl2] (bzpy = 2-benzylpyridine), as a cytotoxic agent (Au(drug)@DFMSNs). The products, including the Au(III) complex, DFMSNs, and Au(drug)@DFMSNs, were characterized by transmission electron microscopy (TEM), field-emission scanning electron micro...
Source: Journal of Molecular Liquids - Category: Molecular Biology Source Type: research
Authors: Salas-Trevino D, Saucedo-Cardenas O, de Jesus Loera-Arias M, Gerardo De Casas-Ortiz E, Rodriguez-Rocha H, Garcia-Garcia A, Montes-de-Oca-Luna R, Soto-Dominguez A Abstract Currently, nanomedicine is approaching the research of nanomaterials that could work as drug delivery systems, to increase the efficiency, specificity and safety of drugs reducing toxicity and side effects. In this regard, carbon nanotubes have acquired great interest due to their physicochemical properties. The use of platinum-based drugs is facing some troubles in the clinic due to their side effects such as nephrotoxicity, neutropenia,...
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
Publication date: Available online 13 July 2018Source: Journal of Geriatric OncologyAuthor(s): Ginah Nightingale, Rowena Schwartz, Ekaterina Kachur, Brianne N. Dixon, Christine Cote, Ashley Barlow, Brooke Barlow, Patrick MedinaAbstractUnique challenges exist when managing older adults with cancer. Associations between cancer and age-related physiologic changes have a direct impact on pharmacokinetics and pharmacodynamics of cancer therapies and can affect drug dosing, dose intensity, efficacy, safety and quality of life. The breadth and depth of these issues, however, have not been fully evaluated because the majority of c...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
We report a novel and easy-to-fabricate polynuclear nanoparticle based on the collaborative re-assembly of nanoparticles as a robust chemogene co-delivery platform. Specifically, the polynuclear nanoparticle carrying DOX and siBcl-2 exerts... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Poly-ADP ribose polymerase-1 (PARP-1) is a critical enzyme involved in DNA repair.   The inhibition of PARP has emerged as a promising strategy in cancer therapy.  Numerous PARP inhibitors have been developed and advanced into clinical trials, both for use as single agents in specific patient populations and as combination therapies with various chemotherapeutics.  The inductio n of strand break damage to DNA, as has been demonstrated in cancer cells treated with O2-arylated diazeniumdiolates, coupled with inhibition of DNA repair by PARP inhibitors, represents a novel rationale for effective combination the...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Work by theNanotechnology Characterization Laboratory (NCL), a joint initiative of NCI, NIST, and the FDA, has led to the discovery of a novel combination chemotherapy. This combination is shown to have synergistic effects on cytotoxicity to cancer cells in vitro, and to cause a substantial decrease in tumor growth in preclinical tumor models in vivo. Combination therapy using these agents may enhance the response rate of different cancers to these drugs and may significantly reduce side effects by permitting a lower therapeutic dose to be administered. SAIC Frederick'' s Nanotechnology Characterization   Laboratory&n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy